iShares Neuroscience and Healthcare ETFIBRN
Type
ETF
Peer group
Global equity
Net assets
$5.2M
Expense ratio
0.47%
1-year return
+53.7%
3 years, a year
+12.3%
5 years, a year
—
Holdings
84
What it aims to do.
The iShares Neuroscience and Healthcare ETF (the Fund ) seeks to track the investment results of an index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares | 8.57% |
| XENE Xenon Pharmaceuticals Inc | 4.79% |
| AXSM Axsome Therapeutics, Inc. | 4.59% |
| ARWR Arrowhead Pharmaceuticals, Inc. | 4.41% |
| ALKS Alkermes Public Limited Company | 4.20% |
| Centessa Pharmaceuticals Plc | 3.95% |
| ARGX argenx SE | 3.88% |
| PTCT Ptc Therapeutics, Inc. | 3.69% |
| NBIX Neurocrine Biosciences, Inc. | 3.69% |
| BIIB Biogen Inc. | 3.67% |
More on IBRN.
- IBRN overview
- IBRN holdings
- IBRN risk
- IBRN costs
- IBRN money in and out
- IBRN share classes
- Compare IBRN with other funds
Returns after fees, from the fund's SEC filings up to Apr 2026. Past returns are not a promise. Not financial advice.